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Abstract 
 
Objective 
 
Renal transplantation is the ideal therapeutic option for patients that reach end-stage renal 
failure. However, patients require long term immunosuppression following surgical 
transplantation to prevent graft rejection [1,2,4]. Mycophenolate mofetil (MMF) had proven 
to be an effective immunosuppressant in transplant patients[8,9,10], although it is 
associated with an increase in gastrointestinal adverse effects, which may result in dose 
adjustment or termination of use [22]. There is a paucity of data regarding gastrointestinal 
side effects of MMF in South Africa. This study attempts to describe the incidence of 
gastrointestinal complications, incidence of dose adjustment and discontinuation of MMF 
due to side effects, to compare the incidence of GI complications between those that had 
prior gastrointestinal ailments and those that had no prior gastrointestinal ailments and 
finally to determine possible risk factors (age, gender, ethnicity, donor type, pre-transplant 
GI diagnosis, pre-transplant diabetes and combination of MMF with tacrolimus) of 
gastrointestinal adverse effects. 
 
Method 
 
Data was collected retrospectively from the file records of the renal transplant unit at 
CMJAH (Charlotte Maxeke Johannesburg Academic Hospital) on adult patients who had 
received kidney transplants between 1998 and 2010 and who had received MMF as part 
of the immunosuppressive regimen for at least the one year post-transplant. Relevant data 
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was captured in an anonymous fashion on a collection sheet. Descriptive analysis of the 
data was carried out. Time-to-event data were analysed by Kaplan-Meier survival analysis. 
The assessment of the effect of prior gastrointestinal ailments, as well as risk factors, was 
carried out by Cox Proportional Hazards regression to estimate the Hazard Ratios. 
 
Results 
 
 
A total of 188 patients were included in the study group, which comprised 65.4% males 
and 32.4% females (2.1% missing data). The mean age at transplant was 38.1 years. The 
patients were predominantly black (69.1%). Donors were predominantly deceased donors. 
Of the 24.5% of donors who were living donors, 76.1% were related living donors, while 
the rest were non-related living donors. The majority of patients (82%) were induced with 
MMF dose of 2 grams per day.  
 
After 5 years, 13.8% of patients discontinued MMF while 86.2% of the patients were still 
on MMF. 48.1% had a dose adjustment due to gastrointestinal side effects. 61% of 
patients had had a diarrhoeal adverse event by 5 years. 21.8% of the patients had 
gastrointestinal side effects other than diarrhoea by 5 years. The combination of tacrolimus 
and MMF was found to be a significant risk factor for diarrhoeal adverse events (Hazard 
Ratio 1.82; 95% CI 1.21-2.73). Having a living donor graft reduced the chance of non-
diarrhoeal gastrointestinal adverse event (Hazard Ratio 0.33; 95% CI 0.13-0.84, p<0.02). 
A trend towards significance was seen in living donors having less diarrhoeal events 
although it did not reach statistical significance (Hazard Ratio 1.32; 95% CI 0.87-2.00, 
p=0.20). 
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Conclusion 
 
As far as the authors are aware, this is the first local study on MMF and GIT adverse effect. 
We found the combination of MMF and tacrolimus is associated with increased risk of 
having diarrhoeal adverse events, which is consistent with international data[34,35]. Living 
donor graft is associated with a lower risk of developing non-diarrhoeal gastrointestinal 
events. Although non-significant, data suggest the same trend favoring living donor graft 
with regards to diarrhoeal events. 
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Chapter One 
 
1.1  Introduction and Literature Review 
 
1.1.1  History of Renal Transplantation 
 
Renal transplantation has become the treatment of choice for modern day patients with 
end-stage renal disease. However, before the era of haemodialysis, death was the usual 
outcome for patients with end stage renal disease. It is thus little wonder that the kidney 
was the first organ to be transplanted in human history. Joboulay first attempted a 
xenograft transplant on two patients in 1906, by transplanting a goat kidney in one and a 
pig kidney in another, and attaching the graft onto the brachial vessels [1,2]. 
Retrospectively, it was obvious that with the primitive surgical technique, sub-optimal post-
procedure care and without any immunosuppressive therapy, the graft failed and both 
patients died soon afterwards. 
 
The first human cadaver renal transplant was pioneered by Voronoy in the former USSR in 
1933. He harvested the graft from a donor that died due to brain injury and transplanted it 
into a 26 year old young female who was dying from acute renal failure due to mercury 
intoxication. The graft kidney was placed into the groin of the recipient. Despite the fact 
that there was no appreciation of ABO-compatibility and warm ischaemic time, the graft 
was harvested from the deceased donor 6 hours post-mortem, the graft produced urine 
after the procedure. The recipient died 4 days later with no thrombosis in the graft 
vasculature. Although for a very brief time period, the graft did function post transplantation. 
This was indeed a milestone in transplant medicine [1,3]. 
2 
 
Several problems hampered the effort of these early transplant pioneers. One of the 
problems was the availability of suitable donor grafts, which still haunts modern day 
transplant units. During the 1950s, transplant units realized the importance of excessive 
ischaemic injury to grafts and there was a movement to utilize live donor grafts, either from 
relatives of the patient or live patients that had been declared brain dead. The positioning 
and vascular anastomosis technique also needed refinement. A kidney anastomosed to 
the arm or thigh vessels was not feasible long term. In 1951, a new technique was 
described in which the graft was placed in an extra-peritoneal position in the iliac fossa, 
whereby the external iliac vessels were easy to access. The bladder is in close proximity 
to implant the ureters. This has since then become the standard procedure [1,3].  
 
The next hurdle was the immune response. Foreign agents induce a potent immune 
response that protects the host by eliminating the foreign agent. This is beneficial to the 
host in case of an infection or malignancy, but detrimental to the transplanted graft. Initial 
attempts to reduce this reaction in the forms of whole body irradiation did not yield 
satisfactory long term results. Patient often suffered bone marrow aplasia and died of 
infection afterwards [1,2]. The ideal would be a pharmacological agent that could suppress 
the immune system sufficiently to permit graft survival, but specific enough such that other 
protective immune responses remained functional, with acceptable adverse effects.  
 
The first successful agent was azathioprine (AZA). It is a pro-drug of a more toxic 
substance 6-mercaptopurine, which then becomes incorporated into replicating DNA and 
inhibits purine nucleotide synthesis and metabolism. It also blocks the de novo pathway of 
purine synthesis and inhibits lymphocyte proliferation. Major adverse effects are also 
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linked to the haematological system, with leucopenia and bone marrow suppression being 
the most serious. Combined with prednisolone, azathioprine enabled the transplantation of 
unrelated donor kidneys with around 50% still functioning at 1 year [1]. 
 
The next step in chemical immunosuppression was the advent of cyclosporine. It allowed 
selective immune regulation of T cells without excessive toxicity. It was isolated from the 
fungus Tolypocladium Inflatum. Cyclosporine was first investigated as an anti-fungal 
antibiotic but its spectrum was too narrow to be of any clinical use. Borel discovered its 
immunosuppressive activity in 1976, which led to further investigations into its properties 
and structure. Cyclosporine A was the first of its kind to inhibit functional T lymphocytes 
specifically and reversibly. It inhibits the production of T cell growth factors like interleukin-
2(IL-2) by binding with intra-cellular proteins called immunophilins, which then inhibit 
calcineurin. Inhibition of calcineurin blocks activation of early T-cell specific genes and 
ultimately results in inhibition of T-cell proliferation [1,4]. 
 
Due to its specific target, cyclosporine made immune suppression more tolerable and less 
toxic to the bone marrow. In 1983 cyclosporine was approved for clinical use to prevent 
graft rejection in transplantation. Cyclosporine dramatically improved the results of kidney 
transplantation. Today, 90–95% of kidney transplants on cyclosporine survive 1 year [1]. 
Since then, cyclosporine had been used with success in transplantation of various solid 
organs, such as heart, lung, pancreas and liver [1,4].  
 
Tacrolimus is a newer agent that falls in the same class as cyclosporine, as both inhibit 
calcineurin albeit via slightly different mechanism. Tacrolimus binds to a different 
immunophilin, the FK506 binding protein (FKBP12). The combined complex then binds to 
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a different site on calcineurin to achieve the same effect as cyclosporine. It is more potent 
and shares a similar toxicity profile as cyclosporine. Well recognised adverse effects 
include neurotoxicity, post-transplant diabetes and nephrotoxicity [4]. Interestingly 
tacrolimus is also implicated in post-transplant diarrhoea, both in combination with MMF 
and AZA [5]. 
 
Three vital steps of an immune response should be targeted to achieve adequate immune 
suppression; first, T cell recognition of foreign antigen presented by antigen-presenting 
cells such as B lymphocytes, dendritic cells and macrophages, second, co-stimulatory 
interactions on the antigen-presenting cells and T lymphocytes, and lastly, when the above 
two steps are completed, activation of calcium-calcineurin pathway which activates and 
induces proliferation of T lymphocytes. Current immuno-suppressive therapy meets the 
challenge by using a triple drug regimen, which consists of corticosteroid, a calcineurin 
inhibitor (such as cyclosporine or tacrolimus) with an anti-metabolite (such as MMF or AZA) 
[3]. Triple therapy combines drugs that have different mechanisms of action and toxicity 
together to ensure maximal effectiveness with minimal adverse effects. The same principle 
is evident in cancer chemotherapy and anti-retroviral therapy [4]. 
 
A high level of immune suppression is required initially after transplant to prevent acute 
and hyper-acute rejection. This is achieved by using high doses of immune suppressants 
with or without combination of biologic antibodies against T cells. Thereafter, the dose can 
be reduced gradually to a lower maintenance level [1,4]. The most common regimen used 
today in kidney transplantation is a CD25 monoclonal antibody such as basiliximab, 
followed by a combination of tacrolimus, mycophenolate, and steroids [1]. 
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1.1.2  What is Mycophenolate Mofetil (MMF)? 
 
MMF is an ester pro-drug of mycophenolate, which was derived from the fungal species 
Penicillium. Discovered in 1893, it was the first antibiotic crystallized and purified from a 
mould. Although mycophenolate was not an effective antibiotic agent, there was interest in 
its potential as an anti-neoplastic and immunosuppressive agent. Mycophenolate was only 
recognized as an immunosuppressant in the 1970s by Anthony Allison, a South African 
born medical scientist who graduated from the University of Witwatersrand, for its powerful 
inhibition of inosine-monophosphate-dehydrogenase and subsequent role as an immuno-
suppressant. After several years of in vitro studies, he devised a more bio-available and 
tolerable pro-drug, mycophenolate mofetil which finally marketed as CellCept and was 
approved for use in renal transplant by the FDA in 1995[6]. 
 
The main mechanism of action of mycophenolate is the inhibition of inosine 
monophosphate dehydrogenase as mentioned before, which is a key enzyme in the de 
novo pathway of purine synthesis. This depletes guanine nucleotides, impairs DNA 
synthesis and thus arrests cell proliferation [4,5,7]. Different cells in the human body rely 
on the de-novo pathway for purine synthesis to a different degree. Neurons employ both 
the salvage pathway and the de novo pathway as compared to lymphocytes, which 
depends almost exclusively on the de novo pathway. Thus mycophenolate can selectively 
inhibit lymphocyte proliferation and suppress immune function [5,7]. 
 
After oral administration, MMF is absorbed and broken down to form the active metabolite, 
mycophenolic acid(MPA). The bioavailability of mycophenolic acid (MPA) following oral 
administration is approximately 90%. The half-life of MPA, including enterohepatic re-
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circulation is 15.8 hours with a peak plasma concentrations occurring at 0.6 to 0.7 hours. 
UDP-glucuronosyl transferase (UDPGT) in the intestine and liver inactivates MPA by 
converting it into MPA-7-O-glucuronide (MPAG). MPAG then undergoes enterohepatic 
recirculation, enabling effective plasma concentrations of the drug to be sustained. 93% of 
the drug is eliminated in the urine, while 6% of the drug is eliminated in stool [4,5,7].  
 
1.1.3  Rationale for MMF Use 
 
MMF had been shown to decrease acute rejection rates significantly after renal 
transplantation in combination therapy [8,9,10]. All three referenced trials have similar 
designs. The US trial by Sollinger compared MMF 2g and 3g group to azathioprine (AZA) 
with the same follow-up period [8]. The European study compared MMF 2g and 3g group 
to placebo on the background of combination therapy with cyclosporine and corticosteroids 
during the first 6 months of transplantation [9]. The Tricontinental Mycophenolate Mofetil 
Renal Transplantation Study also compared MMF at 2g and 3g dose to AZA and followed-
up for 12 months post transplantation [10]. 
 
In the US renal transplant MMF group study, biopsy-proven acute rejection episodes or 
treatment failure occurred in 47.6% of patients in the AZA group compared with 31.1% in 
the MMF 2g treatment group (p=0.0015) and 31.3% in the MMF 3g group (p=0.0021). It 
can be deduced that significantly fewer acute rejection episodes or treatment failure 
occurred in the MMF groups. However, the cumulative incidence of graft loss and patient 
death was comparable amongst the three treatment groups with 10.4% (AZA group), 
5.5%(MMF 2g group) and 8.5%(MMF 3g group). Graft rejection was the predominant 
cause of graft loss. A slight increase in patient death at 6 months in the MMF 3g group of 
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5.5% was noted, as compared to 3% in the AZA group and 3.6% in the MMF 2g group. 
This was due to the higher incidence of infection [8]. 
 
In the European MMF study, significantly more patients in the placebo group had acute 
graft failure confirmed on biopsy compared to either of the MMF groups. The addition of 
MMF was associated with 60-70% reduction in the frequency of acute rejection episodes 
compared with placebo group. The actual percentage for biopsy proven rejection was 
46.4% in the placebo group, 17% in the MMF 2g group and 13.8% in the MMF 3g group 
(p<0.001). Greater efficacy was found in the 3g group than the 2g group, however this was 
offset by more treatment failure due to adverse events (13.3% vs 25%, p<0.001) [9]. 
 
Similar findings were reported in the Tricontinental trial. By 6 months, treatment failure, 
which included rejection, graft loss, death, and discontinuation of study drug occurred in 
50% of patients in the AZA group, compared with 34.8% in the MMF 3g group and 38.2 % 
in the MMF 2g group. Pair wise comparison showed no difference between the MMF 
groups, but did show an important difference between both of these groups and the AZA 
group (MMF 3g vs. AZA: p=0.0045, MMF 2g vs. AZA: p=0.0287). Biopsy-proven rejection 
occurring in 15.9% of patients in the MMF 3g group and 19.7% in the MMF 2g group, 
compared with 35.5% in the AZA group. At 1 year after transplantation, the investigators 
found that graft survival in the MMF groups was marginally superior to that in the AZA 
group, although this difference was not statistically significant. The investigators further 
concluded that MMF is associated with a significantly lower rate of treatment failure 
compared with AZA during the first 6 months after renal transplantation and produces a 
clinically important reduction in the incidence, severity, and treatment of acute graft 
rejection. These differences persist throughout the first year of follow-up [10].  
8 
 
The above 3 studies had proven that MMF is an effective immunosuppressive agent in 
renal transplantation by reducing the incidence of biopsy-proven rejection. One noticeable 
trend is that although the higher MMF dose group have fewer rejection episodes, adverse 
events tend to increase with higher dose of MMF. In the European study, the investigators 
specifically mentioned the increase in leukopaenia and GI adverse events in both the MMF 
groups [9]. The Tricontinental study also found that clinical benefit was greatest with a 
dose of MMF 3 g/day, but gastrointestinal effects, invasive cytomegalovirus infection, and 
malignancies were slightly more common at that dose [10]. 
 
All 3 of the above studies mostly looked at 6 months post-transplantation. The 
investigators hoped that the decrease in acute rejection in the first 6 months would 
translate into long term benefits as well. At the time, MMF had just been approved by FDA, 
thus it was impossible to obtain long term data. The investigators all did a 3-year follow-up 
on the original study. In the European study, 491 participants were included in the analysis. 
The 3-year patient survival was 88.9% in the placebo group, 92.7% in the MMF 2 g group, 
and 91.8% in the MMF 3 g group. The overall 3-year graft survival was 78.0% in the 
placebo group, 84.8% in the MMF 2 g group, and 81.2% in the MMF 3 g group. When 
compared with placebo, MMF 2 g had a significant difference in survival curves over the 3-
year period [11]. 
 
In the Tricontinental follow-up at 3 years after transplant, both intent-to-treat and on-study 
analyses of graft and patient survival showed a trend toward advantage for MMF 2 g and 3 
g vs. AZA, although this trend did not reach statistical significance. Gastrointestinal toxicity, 
leukopenia, and tissue-invasive cytomegalovirus disease were more common in the MMF 
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3 g group both during and after the first post transplant year. Mortality was comparable in 
all three groups (AZA, 8.6%; MMF 2 g, 4.7%; MMF 3 g, 9.1%) by 3 years of follow-up [12]. 
 
Furthermore, a review of the US renal transplant scientific registry suggested that MMF 
decreased the relative risk for development of chronic allograft failure by 27%, 
independent of its outcome on acute rejection [7,13]. Both 4-year patient survival (91.4% 
versus 89.9%) and graft survival (85.6% versus 81.9%) were better for those patients 
receiving MMF than for those receiving AZA [13]. Similar results were published by 
Merville et al, whereby the number of patients with chronic allograft nephropathy at 1-year 
post-transplantation was significantly reduced in the MMF group (46% versus 71%) 
compared with the AZA group [14].  
 
It appears from the above that MMF preserves graft function effectively by preventing 
acute rejection as well chronic allograft nephropathy [7,13,14], which positions MMF as an 
ideal immunosuppressive agent in a combination regimen. It is not without disadvantages 
though, and the most common adverse effects, emerging from all 3 pivotal studies, are 
hematological and gastrointestinal. This study shall focus on the gastrointestinal adverse 
effects. 
 
1.1.4  Gastrointestinal Adverse Effects of MMF and Post-Transplant Diarrhoea 
 
Gastrointestinal toxicity is a major adverse effect of MMF [15]. In the European MMF study 
group trial, up to 52.5% of patients treated with MMF 3g daily developed gastrointestinal 
side effects [9]. In the US trial by Sollinger et al, 31,5% and 37.3% of patients treated with 
MMF 2g and 3g per day respectively developed diarrhoea as compared to 23,8% from 
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azathioprine group at 6 months [8]. A similar comparison is shown in the Tricontinental trial, 
whereby 28% and 31% of the MMF group developed diarrhoea, compared to only 17% 
from azathioprine group at 12 months [10]. The consistency of higher gastrointestinal 
adverse effects with higher MMF dosage suggest that this may be dose related [15].  
 
While adverse gastrointestinal effects range from abdominal cramps, bleeding, nausea 
and vomiting, diarrhoea is the most common gastrointestinal side effect associated with 
MMF. Intestinal epithelial cells are about 50% dependent on the de novo pathway for 
purine synthesis. MMF inhibits this pathway and could potentially inhibit enterocyte 
replication and fluid absorption [15]. This may explain the high incidence of gastrointestinal 
adverse effects especially diarrhoea, observed in the trials [8,9,10]. Case reports have 
shown intestinal villous atrophy following MMF administration causing diarrhoea, which 
resolved following MMF withdrawl [16,17].  
 
The etiologies of diarrhoea in transplant patients are often multi-factorial. They may be 
related to immune suppression, infection by various organisms, other medical co-
morbidities or that of direct toxicities from the immune suppressive medication. The 
addition of MMF in a multi-drug regimen enhances immune suppression and increases  
susceptibility to various intestinal infections [15]. A case report from Guerard et al 
described two cases of microsporidiosis with chronic intractable diarrhoea and associated 
weight loss. Symptoms persisted despite treatment and only subsided with the substitution 
of MMF with azathioprine [18]. A series of 26 patients on MMF with persistent diarrhoea, 
by Maes et al, showed that all but one patient had enterocolitis on histology and that about 
60% of these were due to infection. Again, reduction or cessation of MMF therapy was the 
only effective therapy [19]. 
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However, adjusting the dose can have detrimental effects on the graft. Knoll et al in a 
study of 213 renal transplant recipients, found that the cumulative number of days with the 
MMF dose reduced below full dose was an independent predictor of acute rejection. The 
relative risk of rejection increased by 4% for every week that the MMF dose was reduced 
below full dose. However, there was no significant association observed between the 
number of days with MMF dropped below full dose and chronic allograft failure [20]. 
Pelletier et al, in a study of 721 recipients, found that those with a dose adjustment of MMF 
within the first transplant year had significantly higher incidence of acute rejection (23.3%) 
as compared to those without a dose adjustment (3.7%) [21]. This demonstrated that 
suboptimal MMF exposure in the early post-transplant period predisposes to higher risk of 
acute rejection. 
 
In a retrospective study reviewing records of 772 patients, Tierce et al found that 49.7% of 
patients experienced at least one GI complication within the first 6 months post-transplant, 
out of which, 39% (n=149) experienced MMF dose adjustments or discontinuation of MMF 
therapy. Out of those that had MMF dose adjustments due to GI complications, a 
significantly increased incidence of acute rejections (30.2% vs 19.4%) was found as 
compared to those without [22].  
 
Tacrolimus, in combination with MMF also increases the risk of post-transplant diarrhoea. 
The Symphony Study, which compared 4 treatment groups: standard dose cyclosporine, 
low dose cyclosporine, low dose tacrolimus and low dose sirolimus, all in combination with 
daclizumab, MMF and steroids, concluded that low-dose tacrolimus provided adequate 
immunosuppression with better renal function and less acute rejection. However, Kaplan–
12 
Meier estimates for diarrhoea differed significantly between the groups (P<0.001), with the 
lowest rates occurring in the two cyclosporine groups (15.6% and 13.0% respectively), 
while the highest rate was in the low dose tacrolimus group (25.3%). The higher rate of 
diarrhoea in the low dose tacrolimus group persists in the three-year follow-up study (33%), 
compared to the standard and low dose cyclosporine group (23% and 18 %, p<0.0001) 
[23]. In the DIDACT study, which involved 16 transplant centers in Belgium, 108 patients 
with severe diarrhoea (≥3 stools/day for ≥7 consecutive days) irrespective of the time from 
transplant and immunosuppression, were enrolled. The majority of the patients were on 
MMF (n=96) and tacrolimus (n=70). The investigators found that MMF was associated with 
the largest number of dose reductions or termination (n = 34, 35%), followed by tacrolimus 
(n = 12, 17%) due to post-transplant diarrhoea [24]. 
 
From all of the above, one can conclude that GI complications are common in those that 
receive MMF as part of their regimen. GI complications themselves often leads to dose 
adjustment or termination, which may predispose patients to a higher risk of acute graft 
rejection. This also leads to higher health cost for the patient. Tierce el al found that mean 
incremental cost for patients experiencing GI complications was 3700 USD per patient 
during the 6 months post-transplant [22]. This is unaffordable in a resource limited setting 
such as South Africa. The aim of this study is to determine if there are any clinical criteria 
that one can easily use to predict which group of patients receiving MMF are likely to have 
GI complications, in order to assist clinicians choosing immunosuppressive regimens. 
 
1.2 Research Objectives 
 
To our knowledge, there has been no similar study conducted in South Africa, 
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investigating the gastrointestinal adverse effects of MMF. Research objectives are stated 
below: 
 
1. Describe the incidence of discontinuation of MMF due to GI side effects. 
2. Describe the incidence of dose adjustment of MMF due to GI side effects. 
3. Describe the incidence of GIT complications in the study group. 
4. Compare the incidence of GIT complications between those that had prior GI 
ailment and those that had no prior GIT ailments. 
5. Determine the effect of possible risk factors (age, gender, ethnicity, donor type, 
diabetes, tacrolimus exposure) on GIT side effects. 
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Chapter Two 
 
2.1 Methodology 
 
2.1.1  Study Setting 
 
The study was conducted in the renal transplant unit at Charlotte Maxeke Academic 
Hospital(CMJAH) in Johannesburg, Gauteng Province. The Unit provides renal transplant 
services for the City of Johannesburg as well as the southern part of Gauteng Province 
and part of North West Province. 
 
2.1.2  Study Design 
 
This was a retrospective observational study to determine any possible risk factors for 
transplant patients that are on mycophenolate mofetil (MMF) that develop gastrointestinal 
side-effects that lead to dose adjustment/discontinuation. Data was collected anonymously 
from patient records in the CMJAH renal transplant unit from January 1998 till December 
2010. 
 
2.1.3  Study Population 
 
Bearing in mind the multitude of socio-economic factors in post-Apartheid South Africa, 
public hospitals serve wide geographical areas with variable socio-economic groups. The 
patient population studied comprised of a mixed racial group with lower socio-economic 
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status.  
 
2.1.4  Inclusion Criteria 
 
 All adult patients over the age of 18 years that received kidney allograft in CMJAH 
from 1998 till December 2010.  
 Mycophenolate mofetil needed to be part of the immunosuppressive regime for at 
least a year.  
 To exclude surgical causes of early graft failure, only those whose graft survived the 
first 6 months of transplant were included. 
 
2.1.5  Exclusion Criteria 
 
Incomplete patient file records were not included in the study. 
 
2.1.6  Instruments 
 
A data capture sheet was created to collect relevant epidemiological data (i.e. age, gender, 
race group, year of transplant, age at transplant) as well as variables such as prior 
gastrointestinal diagnosis, date of gastrointestinal events and date of change in 
immunosuppressive regimen. (Annexure 1) from patient file records. A study number on 
the data collection sheet was generated which could be matched to the patient's name and 
date of birth on a separate sheet (Annexure 2), and thus data could be accurate tracked 
while ensuring patient confidentiality.  
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2.2  Data Analysis 
 
2.2.1  Statistical Analysis 
 
A descriptive analysis of the data was carried out as follows: Categorical variables were 
summarised by frequency and percentage tabulation, and illustrated by means of bar 
charts. Continuous variables were summarized by the mean, standard deviation, median 
and interquartile range, and their distribution illustrated by means of histograms. Time-to-
event data were analyzed by Kaplan-Meier survival analysis. The assessment of the effect 
of prior GI ailments, as well as risk factors, was carried out by Cox Proportional Hazards 
(PH) regression to estimate the Hazard Ratios (HRs). At least 10 events per estimated 
parameter were required. The Cox PH regression analysis was carried out for diarrhoeal 
and non-diarrhoeal complications separately.  In each case, each risk factor was examined 
on its own, after which risk factors with p<0.20 were combined in a multivariate regression. 
Confounding relationships between risk factors combined in a multivariate regression were 
assessed by determining the strength of the association between each pair of risk factors 
(phi coefficient or Cramer’s V for pairs of categorical variables, or Cohen’s d for 
categorical-continuous variable pairs). Data analysis was carried out using SAS. The 5% 
significance level was used. In other words, p-values <0.05 indicate significant results. 
 
2.2.2  Sample Size 
 
Calculation of sample size requirements was based on the key research question to be 
answered, in this case, the hazard ratio for gastrointestinal complications amongst those 
who had prior gastrointestinal ailments versus those who did not. Assuming equal group 
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sizes, a hazard ratio of 1.5, a median survival time (to GI complication) of 1 year, a 
censoring rate of 10%, and an average follow-up duration of 5 years, a significance level of 
5% and 80% power, a sample size of 216 is required. Thus, the actual sample size of 188 
is adequate for a study of this nature. 
 
2.3  Ethical Considerations 
 
The researcher has no conflict of interest. Two separate data collecting sheets were used 
to ensured anonymity. The use of unrelated record numbers on the data sheets further 
ensure anonymity. No personal details except those pertaining to the study are recorded. 
Due to the retrospective nature of this study, no direct contact with patients was required. 
This study was approved by the University of Witwatersrand Human Research Ethics 
Committee, protocol reference number M141126. The use of hospital records was 
approved by the CEO's office of CMJAH. The relevant documentation is attached in 
Annexure 3 and 4. 
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Chapter Three 
 
3.1 Descriptive Analysis of Study Group 
 
A total number of 399 traceable records of transplant recipients were found. Out of which 
41 (10%) had incomplete file records. A total of 188 (52.5%) out of 358 file records met the 
inclusion criteria and were included for the study. In the study group, 70.7% (n=133) of the 
patient survived without rejection past 5 years post-transplant, 11.1% (n=21) lost to follow 
up, 12.7% (n=24) rejected and 5.3% (n=10) demised. 
 
Description of the study population are presented under the following heading, 
 Year of Transplant 
 Age of Transplant 
 Gender Distribution 
 Ethnicity 
 Graft Type 
 Combination of tacrolimus and MMF 
 
3.1.1  Year of Transplant 
 
The distribution of the study group with respect to the year of transplant are shown in the 
following graph. 
 
19 
Figure 1. Distribution of patient numbers over the study period in years AD. 
 
3.1.2  Age at Transplant 
 
The mean age at transplant was 38.1 years (SD=10.6 years; range 18.4-66.3 years).  The 
distribution of the ages is shown below: 
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Figure 2. Age distribution of patients in the study 
 
3.1.3  Gender Distribution 
 
The study group comprised 65.2% males (n=123) and 32.2% females (n=61). 4 files (2.1%) 
have missing or unclear data with regards to gender. There is a preponderance of male 
gender in the study population.  
 
21 
 
Figure 3. Gender distribution of the patients in the study group 
 
3.1.4  Ethnicity 
 
As reflected by the general population, majority (n=130, 69.1%) of the patients are black. 
 
Figure 4. Ethnicity distribution of the study population.  
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3.1.5  Graft Type 
 
There were 142 (75.5%) cadaveric donors. Of the 46 (24.4%) donors who were living 
donors, 35 (18.6%) were related living donors, while 11 (5.8%) were non-related living 
donors. 
 
 
Figure 5. Bar chart demonstrating the three types of donor grafts: cadaveric, related living 
donor graft and non-related living donor graft. 
 
3.1.6  Pre-transplant GI Diagnosis 
 
The level of missing data for this variable is in excess of 30% (37.8%) which means that 
this variable cannot be analysed at all. This unfortunately means that we will not be able to 
address some of the study objectives. 
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3.1.7  Pre-transplant Diabetes 
 
The level of missing data for this variable is in excess of 30% (37.8%) which means that 
this variable cannot be analysed at all.  This unfortunately means that we will not be able 
to address some of the study objectives. 
 
3.1.8  MMF Induction Dose 
 
The distribution of the data is shown below.  The majority of patients were initiated on a 
dose of 2 grams daily. 0 g means that the patient did not initiate on MMF, only changed to 
MMF later on. 
 
 
Figure 6. Bar chart showing MMF induction dose.  
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3.1.9 Combination of Tacrolimus and MMF 
 
59 out of 188 patients enrolled had been exposed to combination of tacrolimus and MMF 
as part of the multi-drug immune suppression regimen, which translates to 31.4% of the 
total study population. 
 
3.2  Statistical Analysis of Study Data 
 
The aims of this study were to describe incidence of discontinuation and/or the incidence 
of dose adjustment of MMF due to GI side effects, the incidence of GIT complications in 
the study group and then, compare the incidence of GIT complications between those that 
had prior GI ailments and those that had no prior GIT ailments. Finally, we want to 
determine the effect of possible risk factors (age, gender, ethnicity, donor type, diabetes) 
on GIT side effects. 
 
3.2.1  Discontinuation of MMF due to GI side effects 
 
The median follow-up time for the study group (until MMF discontinuation due to GI 
adverse events, death, or loss to follow-up) was 4.6 years. 
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Figure 7. Kaplan-Meier survival curve for time until MMF discontinuation due to GI adverse 
events is shown. The data beyond 10 years should not be interpreted, due to the low 
number of subjects at risk. 
 
The survival estimates (i.e. the percentages of cases who did not have MMF discontinued 
due to GI side effects) at 1, 3, 5, and 10 years after transplant are tabulated below.  Thus, 
we can conclude that, after 5 years, 91.6% of the patients were still on MMF (and so on). 
Time (years) Survival (%) 95% CI for survival  
1 98.9% 95.7% 99.7% 
3 94.1% 89.3% 96.8% 
5 91.6% 85.8% 95.1% 
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10 81.3% 72.0% 87.8% 
Table 1. Percentage of patients that continued MMF over time 
 
3.2.2  Dose adjustment of MMF due to GI side effects 
 
The median follow-up time for the study group (until MMF dose adjustment, MMF 
discontinuation, death, or loss to follow-up) was 3.1 years. The Kaplan-Meier survival 
curve for time until MMF dose adjustment due to side effects is shown below. The data 
beyond 8 years should not be interpreted, due to the low number of subjects at risk.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Kaplan-Meier curve showing patients that continued on induction dose of MMF 
over time. 
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The survival estimates (i.e. the percentages of patients who are on induction dose of MMF) 
at 1, 3, 5, and 8 years after transplant are tabulated below. After one year, 13.4% of 
patients have their MMF dose adjusted. After 5 years after transplant, 48.1% (n=90) had a 
dose adjustment due to GI adverse events. 
 
Time (years) Survival (%) 95% CI for survival  
1 86.6% 80.9% 90.8% 
3 66.3% 58.7% 72.8% 
5 51.9% 43.4% 59.8% 
8 41.7% 32.6% 50.4% 
Table 2. Table showing percentage of patients on induction dose of MMF over time. 
 
3.2.3   Incidence of GI complications 
 
The data is analyzed by dividing GI complications into diarrhoeal and non-diarrhoeal 
events. 
 
3.2.3.1 Incidence of Diarrhoeal Complications 
 
The median follow-up time for the study group (until first episode of diarrhoea, MMF 
discontinuation, death, or loss to follow-up) was 2.6 years. The Kaplan-Meier survival 
curve for time until the first episode of diarrhoea is shown below. The data beyond 8 years 
should not be interpreted, due to the low number of subjects at risk. 
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Figure 9. Kaplan-Meier graph depicting patients that did not have diarrhoea over time 
 
The survival estimates (i.e. the percentages of cases who did not have diarrhoea) at 1, 3, 
5, and 8 years after transplant are tabulated below. Thus, one can conclude that, after 5 
years, 39.0% (n=73) of the patients had not experienced diarrhoea as an adverse event, 
while 61% (n= 115) had. 
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Time (years) Survival (%) 95% CI for survival  
1 78.6% 72.0% 83.8% 
3 55.7% 48.0% 62.7% 
5 39.0% 30.9% 47.0% 
8 30.7% 22.5% 39.3% 
Table 3. Table depicting percentage of patients who did not have diarrhoea over time. 
The median time to the first diarrhoeal event was 3.6 years (95% CI: 2.8-4.4 years). Of the 
109 patients who had a diarrhoeal event, 22 subsequently discontinued MMF (20.2%), and 
80 had a dose adjustment (73.4%). 
 
3.2.3.2 Incidence of Non-diarrhoeal GI complication 
 
The median follow-up time for the study group (until first episode of non-diarrhoeal GI 
complication, MMF discontinuation, death, or loss to follow-up) was 3.6 years. The Kaplan-
Meier survival curve for time until the first episode of non-diarrhoeal GI complication is 
shown below. The data beyond 8 years should not be interpreted, due to the low number 
of subjects at risk. 
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Figure 10. Kaplan-Meier graph showing patients that are free of non-diarrhoeal 
complications over time. 
The survival estimates (i.e. the percentages of cases who did not have a non-diarrhoeal 
gastrointestinal complication episode) at 1, 3, 5, and 8 years after transplant are tabulated 
below. Thus, one can conclude that, after 5 years, 78.2% (n=147) of the patients had not 
had a non-diarrhoeal gastrointestinal complication, while 21.8% (n=41) had a non- 
diarrhoeal gastrointestinal complication. 
Time (years) Survival (%) 95% CI for survival  
1 91.4% 86.3% 94.6% 
3 83.1% 76.7% 87.9% 
31 
5 78.2% 70.7% 84.1% 
8 70.2% 60.6% 77.9% 
Table 4. Percentage of patients that did not have non-diarrhoeal complication over time 
 
Of the 46 patients who had a non-diarrhoeal complication, 11 subsequently discontinued 
MMF (23.9%), and 13 had a dose adjustment (28.3%). 
 
3.2.4  Comparing the incidence of GI complications between patients that had  
  prior GI ailments and those that had no prior GI ailments 
 
This objective cannot be addressed due to the large amount of missing data in the pre-
transplant GI diagnosis variable as mentioned previously. 
 
3.2.5   Determining Possible Risk Factors of GI Adverse Events 
 
There are enough cases in the smallest group (either event or non-event) for each of the 
outcome variables to allow analysis. 
 
 Diabetes was excluded from this analysis due to the high levels of missing data (as 
discussed earlier). 
 Ethnicity:  Coloured and Asian were combined due to their small group sizes. 
 Donor type:  RLD and NRLD were combined due to the small group size for NRLD. 
 The following reference categories were used for the categorical risk factors:  
Gender: male; Ethnicity: Black; Donor type: cadaver; Combination of tacrolimus and 
MMF. Age at transplant was used as a continuous variable. 
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3.2.5.1 Risk Factors for Diarrhoeal Adverse Event 
 
 
Parameter Reference 
category 
Category p-value Hazard 
Ratio 
95% CI for Hazard 
Ratio 
Age at transplant - - 0.50 0.99 0.98 1.01 
Sex M F 0.50 1.15 0.77 1.71 
Ethnicity B A/C 0.34 0.73 0.39 1.39 
W 0.43 1.20 0.77 1.88 
Graft type CD RLD/NRLD 0.20 1.32 0.87 2.00 
Combination of 
tacrolimus and 
MMF 
No Yes 0.0038 1.82 1.21 2.73 
Table 5. Table depicting risk factors for diarrhoeal adverse event 
 
Combination of tacrolimus and MMF was a significant risk factor. It increases the risk of a 
diarrhoeal event (Hazard Ratio 1.82; 95% CI 1.21-2.73) as illustrated below: 
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Figure 11. Kaplan-Meier survival curve comparing tacrolimus exposure to non-tacrolimus 
exposure in patients already on MMF therapy. 
 
None of the other risk factors was significant when considered individually. No p-values 
were below 0.20, thus no multivariate analysis was carried out. 
 
3.2.5.2 Risk Factors for Non-Diarrhoeal GI Adverse Events 
 
Parameter Reference 
category 
Category p-
value 
Hazard 
Ratio 
95% CI for Hazard Ratio 
Age at transplant - - 0.47 0.99 0.96 1.02 
Sex M F 0.49 1.24 0.67 2.29 
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Ethnicity B A/C 0.55 0.75 0.29 1.94 
W 0.26 0.63 0.28 1.42 
Graft type CD RLD/NRLD 0.020 0.33 0.13 0.84 
Combination of 
tacrolimus and 
MMF 
No Yes 0.83 1.08 0.55 2.10 
Table 6. Table depicting risk factors for non-diarrhoeal gastrointestinal adverse event 
 
Graft type was a significant risk factor. Having a living donor graft (compared to a 
cadaveric graft) reduced the risk of a non-diarrhoeal event (Hazard Ratio 0.33; 95% CI 
0.13-0.84) as illustrated below: 
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Figure 12.  Kaplan-Meier survival curve comparing cadaveric (CD) versus living donor (LD) 
graft with regards to other non-diarrhoeal gastrointestinal adverse events. 
 
No other risk factors had p-values below 0.20, thus no multivariate analysis was carried 
out. 
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Chapter Four 
 
4.1  Discussion of Descriptive Analysis 
 
4.1.1.  Gender 
 
The study population were predominantly males (65.2%). The same trend can be seen in 
the US 2011 transplant data, whereby 16,816 renal transplants were performed with 
10,235 (60.8%) male recipients and 6,581 (39.1%) female recipients [25]. One may argue 
that females are traditionally disadvantaged in the South African society thus have less 
resources to seek health care. However, if the above hypothesis stands to reason, then in 
a more developed and sophisticated first-world country such as USA, one expects a more 
balanced gender representation of renal transplant recipients. This clearly is not the case, 
suggesting perhaps an underlying biological reason for the apparent gender discrepancy.  
 
Goldberg et al, after examining all the recent literature in a review article, concluded that 
the prevalence of CKD tends to be higher in females, whereas the disease is more severe 
with a higher progression rate in males [26]. Neugarten suggested a possible hormonal 
mechanism to explain the gender discrepancy. Various renal benefits of estrogen include; 
reduction in the expression of renin, ACE, and angiotensin II on the renin-angiotensin 
system; inhibition of endothelin (a potent vasoconstrictor and promotes sodium retention) 
synthesis; suppression of superoxide anion generation and decrease apoptosis of kidney 
podocytes; all of which have a renal protective effect [27]. These effects may contribute to 
alterations in kidney haemodynamics and slows kidney disease progression in females. 
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Hence it may explain the difference in gender distribution in the transplant population. 
 
4.1.2  Age 
 
Mean age of the study population is 38.2 years. In the 2011 US transplant data, the 
majority of the recipients are between the age of 50-64 (39.7%) [25]. Since age is a well-
known risk factor for chronic renal disease, our study population is relatively young. This 
could be a reflection of the general younger population and shorter life expectancy in 
South Africa [28].  
 
4.1.3  Type of Graft 
 
The majority of transplanted grafts are deceased donor grafts (75.5%). This largely 
corresponds with US 2011 data (65.6%) [25]. Deceased donor grafts are usually more 
readily available than living donor grafts and that is reflected in this study.  
 
4.1.4  Ethnicity 
 
Black Africans are the major racial group in this study population, which reflects the 
national population of South Africa [27]. In the USA and Europe, there is a predominance 
of Caucasian recipient population which also reflects the general population there [25]. 
Since most of the published data are from USA and Europe, our rather different racial 
profile makes our data unique.  
 
4.2  Discussion of Statistical Analysis 
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4.2.1  Discontinuation and Dose Adjustment of MMF due to GI adverse effects 
 
GI side effects and effects on dosage have been investigated extensively in renal 
transplant recipients, since the earliest three pivotal trials [8,9,10]. We shall discuss dose 
adjustment and termination together for convenience. 
 
Knoll et al in a study of 213 renal transplant recipients, found 59% (n=126) of the patients 
had at least one MMF dose reduction. A total of 176 MMF dose reductions were recorded 
during the course of the study. The most frequent cause for a dose reduction was 
leukopenia (55.1%). MMF dose was reduced because of gastrointestinal symptoms such 
as nausea, vomiting, or diarrhoea (22.2%), infection (7.4%), malignancy (1.1%), and 
unknown reasons (14.2%) in the remainder of cases. MMF was permanently discontinued 
in 16 patients [20].  
 
Pelletier et al, in a single center retrospective analysis of 721 patients, found that dose 
adjustments were common in the first post-transplant year, with 70.3% (n=507) of 
patients having at least one dose adjustment. The majority of the indications for dose 
adjustments were hematological and infectious. GI complications accounted for 21% of the 
dose adjustments. Of the 507 dose-adjusted patients, 102 (20.1%) patients discontinued 
MMF within the first post-transplant year [21].  
 
Tierce et al, in a record review of 768 renal transplant patients who were initiated on MMF 
therapy, reported 49.7% (n=382) patients who experienced GI complications and 39.0% 
(n=149) underwent MMF dose adjustments or MMF discontinuation within the first 6 
39 
months of post-transplant [22].  
 
In the Diarrhoea Diagnosis Aid and Clinical Treatment (DIDACT) study by Maes et al, 
whereby 108 renal transplant patients with severe diarrhoea were enrolled, MMF was 
associated with the largest number of dose reductions (24%) and termination (11%). 
Interestingly, >50% of patients diarrhoea started 2 years or more after transplantation. This 
correlates with our study which found a median time to the first diarrhoeal event was 3.6 
years (95% CI: 2.8-4.4 years) [24].  
 
Hardinger et al in a retrospective review of 6400 MMF treated patients from USRDS, found 
that 27.3% (n= 1753) had GI adverse events, and MMF was discontinued in 17.5% 
(n=1117) of patients after one year. The frequency of MMF discontinuation was 
significantly higher in patients with GI complications than in those without such 
complication (21.3% vs 16.0%, odds ratio 1.33, p<0.0001) [29].  
 
Bunnapradist et al analyzed file records of 3675 patients on MMF therapy and had a GI 
complication. Only 45.7% (n=1681) of the patients remained on full-dose MMF. MMF was 
discontinued in 33.7% (n=1240) of the patients, with a further 12% (n=455) requiring a 
dose reduction >50%. In terms of time to onset of GI complications, 69% of the patients 
had a first diagnosis within the first year post-transplant (median time 166 days) [30]. 
 
The data in some of the studies did not distinguish between dose adjustment and 
termination of MMF. However, the studies points to a discontinuation rate of between 11% 
to 20%, with various follow-up period. Our overall MMF discontinuation rate due to GI 
complications is 18.7%, which largely correlates with other studies [20-22,24,29,30]. The 
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dose adjustment rates among the studies were 22%-54.3% with various follow-up periods 
[20-22,24,29,30]. Our study showed that after one year, 13.4% of patients had their MMF 
dose adjusted. After 3 years, this increased to 33.7% and finally, 5 years after transplant, 
48.1% (n=90) had a dose adjustment due to GI adverse events. Although the follow-up 
period varies from 6 months to 3 years, the result of our study is reasonably consistent 
with the above quoted studies [20-22,24,29,30]. 
 
The minimal one year MMF duration inclusion criteria may have biased our result, as that 
patients who had GI complications and discontinued MMF before one year may be 
excluded. The number of patients excluded by this criterion may be as high as 39% as 
suggested by Tierce et al [22]. Our study was conducted in a later time period when 
physician may have had more knowledge and experience with MMF which may lead to 
less termination. The population is also different both in racial, gender and socio-
economical background. The difference in racial composition of our population compared 
to developed countries like USA, where majority of the data came from, deserves further 
scrutiny. 
 
As mentioned previously, the majority of our study population are black Africans. In a 
subset analysis of the US clinical trial of MMF in renal transplantation [8], Nyelan found 
that dose-dependent prevention of acute rejection in African-Americans is most effective at 
a dosage of MMF at 3g/day, which is more than the 2g/day dose for non-African-
Americans. At 3g/day, African-Americans experienced the same incidence of reported 
adverse events (9.1%) compared with non-African Americans (9.8%) [31]. In a later study 
investigating racial difference in MMF dosing, outcomes and adverse effects in pediatric 
kidney transplant patients, Jensen et al found that African-American pediatric patients 
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receive higher MMF doses within the first three-year post-transplant. The African-American 
population also have a lower incidence of any adverse event compared to non-African-
Americans (44% vs. 51%). Although statistically non-significant, the incidence of GI 
adverse events in African-Americans compared to non-African-Americans was lower (13% 
vs. 26%) [32]. 
 
This suggests there are some differences in pharmacokinetics in African-Americans. In a 
study of MMF pharmacokinetics in 53 renal transplant patients, Tornatore et al MPA 
clearance in African American males was longer (26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in 
Caucasian males p=0.035) with no difference noted in MPA troughs. Enterohepatic 
circulation occurred less frequently in African American males (23%) compared with 
Caucasian males (42%). A racial difference was noted with more rapid MPA clearance in 
African American males compared with Caucasians [33].  
 
Thus, African-Americans have a higher clearance rate of MMF, which is due to less 
enterohepatic circulation of MPA and MPAG. This may account for the higher dose of 
MMF required and less GI adverse events. The difference in racial composition may 
explain the discrepancy between the incidence of GI adverse events found in our study 
compared with international data, especially those from USA. 
 
Another flaw in our dose adjustment is that we derive the data by calculating patients that 
remained on induction dose of MMF. Thus, those that had MMF discontinuation, death, or 
loss to follow-up were indirectly included in the statistical analysis. Similar flaw also applies 
to dose termination data. 
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4.2.2  Incidence of GI complications 
 
The earliest trials such as Sollinger et al, reported 31.5% of patients in the 2g daily MMF 
group had diarrhoea as compared to AZA group at 6-months post transplantation [8]. The 
Europe MMF Cooperative Study group reported 45.5% of patients in the 2g MMF 
treatment group had GI adverse event. Out of those that had GI adverse events, 28% had 
diarrhoea [9]. The Tri-continental group concurred that diarrhoea was more common 
among patients receiving MMF than among those receiving AZA and occurred with highest 
frequency in those receiving the higher dose of MMF (MMF 3g=31%, MMF 2g=28%, 
AZA=17%) [10]. 
 
Later studies also showed a wide range of incidences of GI adverse events. Tierce et al 
demonstrated 49.7% had GI adverse event within the first 6 months post-transplant [22]. 
Hardinger et al found that 27.3% (n=1753) of MMF treated patients had GI adverse events 
in the first year post transplant [28]. Both of these studies did not distinguish diarrhoeal 
with non-diarrhoeal GI adverse events. 
 
In another retrospective analysis of 41 442 patient records, Bunnapradist et al reported 
17.1% (n=7103) of patients had post-transplant diarrhoea in the 3-year study period. The 
authors sub-categorised diarrhoea according to etiologies. Compared with all other 
categories of diarrhoea, the cumulative incidence of unspecified non-infectious diarrhoea 
was the highest during the whole study period. Almost half the cases first occurred in the 
first post-transplantation year [34]. The majority of patients (60%, n=25 014) were on a 
MMF containing regimen, however the author did not report the incidence of diarrhoea on 
the MMF treated patient group. The use of Medicare claim data for the diagnosis of 
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diarrhoea, which often only included severe disease meant that mild diarrhoeal episodes 
may be under-reported. 
 
In our study, the prevalence of diarrhoeal complications is 21.4% in the first year post-
transplantation, which, although different, is comparable with other studies quoted above 
despite a relatively smaller sample size. This increases as follow-up lengthens, resulting 
44.3% at 3 years and 61% at 5 years post-transplant. Overall, 57.9% of the study 
population (n=109) experienced a diarrhoeal adverse event. 
 
However, it is difficult to compare results from these trials to our study, since some studies 
did not distinguish between diarrhoeal and non-diarrhoeal GI adverse events. The wide 
spread of GI adverse event incidence may also be due to lack of clear, uniform definition 
of GI adverse events across the studies. A lot of the GI symptoms relied on patient self-
reporting which is difficult to be verified independently. Our study did not record and sub-
classify the diarrhoeal adverse events according to etiology, which could lead to bias. 
 
The prevalence of non-diarrhoeal GI events is much less: 8.6% at one-year post-transplant, 
16.9% at 3 years and 21.8% at 5 years. The prevalence of non-diarrhoeal GI events also 
increases as follow-up period lengthens. 
 
4.2.3  Risk Factors Contributing Towards GI Adverse Events 
 
Five variables were investigated for possible risk factors contributing towards adverse GI 
events, namely gender, ethnicity, age at transplant, graft type and combination of 
tacrolimus and MMF therapy. Once again, distinction between diarrhoeal and non-
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diarrhoeal events were made when determining risk factors. The combination of tacrolimus 
and MMF was found to be a significant risk factor for diarrhoeal events (Hazard Ratio 1.82; 
95% CI 1.21-2.73), but not non-diarrhoeal events. A living donor graft reduced the risk of 
non-diarrhoeal event (Hazard Ratio 0.33; 95% CI 0.13-0.84). 
 
Bunnapradist et al, in a retrospective analysis of 41 442 Medicare patient records, found 
that female gender is associated with increased risk of all types of diarrhoea. Also, 
regimens based on MMF and tacrolimus were associated with a greater incidence of 
infectious (HR=1.44 (95% CI =1.14-1.81), p<0.05) and unspecified noninfectious diarrhoea 
(HR=1.37 (95% CI =1.28-1.46), p<0.05) [34]. Although our study did not distinguish 
between types of diarrhoea, both studies concurred on tacrolimus being a significant risk 
factor for diarrhoea in MMF treated patients. However, this study did not find gender to be 
a predisposing factor towards post-transplant diarrhoea in patients with MMF containing 
regimen (HR=1.15; 95% CI 0.77-1.71, p=0.50).  
 
A more recent study by Zhao et al, investigating late, non-infectious diarrhoea in renal 
transplant patients receiving MMF with either cyclosporine A or tacrolimus. 541 patients 
were enrolled and followed up for at least 36 months. None of the cyclosporine treated 
patients presented with late, severe, noninfectious diarrhoea compared with tacrolimus 
treated group (n=301), which had 7% (n=21) of late, severe, noninfectious diarrhoea [35]. 
This further supports the result of our study. 
 
The Symphony study was a landmark prospective study in de novo solid organ transplant 
patients. In the 1-year Symphony study, the regimen including daclizumab induction, MMF 
2g daily, low-dose tacrolimus and steroids resulted in better renal function, less acute 
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rejections and less graft losses compared to the other regimens [23]. The benefit 
continued in the subsequent 3-year follow-up study. Low-dose tacrolimus continued to be 
the group with the best outcomes [36]. The Symphony trial had demonstrated that 
combination of MMF and tacrolimus is superior to combination of MMF and cyclosporine A. 
Unfortunately, the combination of MMF and tacrolimus is associated with increased risk of 
post-transplant diarrhoea as mentioned previously. 
 
While Bunnapradist did not theorize on possible mechanisms of the combination of MMF 
and tacrolimus giving rise to more post-transplant diarrhoea, Zhao et al postulated that it is 
due to drug interactions between the two, although no MPA (the active metabolite of MMF) 
levels were done in that particular study [35]. However, there is strong evidence that MPA 
trough concentrations are influenced by tacrolimus. A dose-dependent inhibition of UDP-
glucuronosyl transferase (an enzyme responsible for inactivation of MPA) by tacrolimus, 
leading to an increase in MPA and reduction in MPAG concentrations [7]. Therefore, when 
MMF was co-administered with tacrolimus, the area-under-curve(AUC) values for MPA 
increased with time, such that by 3 months the AUC values were 20–30% higher. 
Tacrolimus co-administration with MMF shows a higher MPA level compared with 
cyclosporine. The pharmacokinetics of tacrolimus are unchanged in the presence of MMF 
[37]. The increase in MPA level when MMF is co-administered with tacrolimus may explain 
the increased risk of diarrhoea associated with co-administration. 
 
This study found that graft type contributed significantly towards the occurrence of non-
diarrhoeal adverse GI events (HR=0.33; 95% CI 0.13-0.84, p=0.02). The result is 
somewhat expected. It is well-known that living donor grafts have better graft survival 
compared with deceased donor grafts [38]. Deceased donor grafts usually have more 
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ischaemic damage, less matching HLA and may require more aggressive immuno-
suppression [39]. In a retrospective cohort study of 218 patients, Nemati et al found that 
although there are no significant differences in one-year survival rates, three-years survival 
rates of patient and graft were significantly longer in living donor kidney transplants in 
comparison with the deceased donor kidney recipients [39]. It is logical to deduce that 
living donor grafts would have less complications than deceased donor grafts.  
 
4.3  Limitations of The Study 
 
The inclusion criteria may be too strict and thus limit the sample size. The inclusion criteria 
was originally thought to exclude acute surgical causes of graft failure. Only 52.5% of 
complete patient records were included after the application of the inclusion criteria, which 
although statistically adequate, is still a small sample compared to other studies. It may not 
be a representative distribution of the general population and thus may introduce bias.  
 
Another important factor is that of incomplete data, especially in the pre-transplant work-up  
file. Missing data resulted in the exclusion of the pre-transplant GI diagnosis from 
statistical analysis, which limits the findings in this study. Since MPA undergoes extensive 
enterohepatic re-circulation, this may be crucial in determining susceptibility to GI 
complications. 
 
There are no clear definitions for diarrhoeal events. Diarrhoeal events relied largely on 
patient reporting, and can vary in severity. The incidence of diarrhoeal event can thus be 
biased, as it cannot be objectively verified. The etiology of the diarrhoea was often not 
investigated in the files and this study did not include the etiology of diarrhoeal event, 
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which may again influence the result. The design of the study also did not include further 
classification of non-diarrhoeal gastrointestinal events.  Further study is needed to include 
a clear definition of diarrhoea and investigate possible causes. 
 
According to Hardinger et al, the greatest risk associated with GI complications was in 
patients with CMV infection (RR= 1.85; p<0.0001). Other factors associated with a 
heightened risk of GI complications were hyperlipidemia (RR=1.29; p<0.0001), post-
transplant diabetes (RR=1.20; p=0.0002), the number of post-transplant hospitalizations 
(RR=1.20; p<0.0001), pre-transplant maintenance peritoneal dialysis (RR=1.21; p=0.0002), 
pre-transplant maintenance haemodialysis (RR=1.39; p<0.0001), and hypertension as the 
cause of ESRD. This study did not include all of the above as possible risk factors to GI 
adverse events. This would be important for future studies. 
 
Some of the other studies also investigated outcomes related to GI adverse events and , 
such as graft loss, death, acute rejection episodes [11,12,13,20,21,22] and financial cost-
effectiveness [22]. This study did not include these parameters into its design. Future 
studies can investigate further the link between GI adverse events and patient outcomes in 
a South African context. 
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Chapter 5 
 
5.1  Conclusion 
 
End-stage renal disease was a terminal illness until the advancement in surgical 
techniques, peri-operative care and medical immunosuppressive therapy made renal 
transplantation a reality. Immuno-therapy had progressed rapidly from the rather primitive 
idea of whole body irradiation to the combination chemotherapy we have today [1,2]. At 
the same time, we are demanding not only better patient survival, but also more tolerable 
side effects and more cost effectiveness. 
 
MMF is one of the many drugs available in the arsenal of immune-suppressive therapy. 
Not only has it proven to be an effective agent at preventing acute graft rejections in large 
randomised control trials [8,9,10], but also in preventing chronic graft failure [7,13,14]. 
Unfortunately, MMF does have side effects that physicians need to be aware of. One of 
the common adverse effects are gastrointestinal. Since the very first pivotal trials, GI 
adverse events were documented as the major side effects in MMF treated renal 
transplant recipients [8,9,10]. These GI adverse effects often lead to dose adjustment or 
discontinuation of the drug, which is linked to more acute rejection episodes and poorer 
patient outcome [20-22].  
 
As far as the authors are aware, this is the first study in South Africa that investigates MMF 
and gastrointestinal adverse events using local data. Our study population is younger and  
made up of more black African population as contrary to most of the published data, which 
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consists of a much older population and more Caucasian racial distribution. Despite this, 
our results in terms of dose adjustment and termination is still reasonably consistent with 
international data. This study found that combination therapy of MMF and tacrolimus is a 
significant risk factor for post-transplant diarrhoea in renal transplant recipients, which 
concurs with Bunnapradist and Zhao [34,35]. This is most likely due to drug interaction. 
Tacrolimus increases MPA level and thus may be associated with more diarrhoeal events 
[37]. Living donor graft is associated with less non-diarrhoeal GI complication in renal 
transplant recipients using MMF as part of the immunosuppressive regime. This could be 
due to less ischaemic injury, better HLA match and less aggressive immunosuppression 
associated with living donor graft [39].  
 
5.2  Recommendation 
 
Future studies in the field of post-transplant diarrhoea, especially in the South African 
setting, should have a more accommodating inclusion criteria to achieve a bigger sample 
size. There should be a clear definition of diarrhoea and perhaps sub-classify diarrhoea 
into categories according to etiology ( eg. infectious vs. non-infectious). Patient and graft 
outcomes can also be included in future studies to determine the consequence of GI 
adverse events in renal transplant patients. Other risk factors such as CMV infection, post-
transplant diabetes and length of dialysis before transplant can also be investigated in 
future studies.  
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Annexure 1 
Data Collection Sheet 
 
Pre-transplant 
 
GI Diagnosis 
 
 
 
 
Gastroscopy Results 
 
 
 
 
Diabetic Pre-transplant         Yes/No 
Acid Suppressive Therapy         Yes/No 
 Medication and Dose 
Record Number:  Age 
 DOT Transplant Age 
Graft Type:              Cadaver / Related Living / Non-Related Living 
Ethnicity:                Caucasian / Black / Indian / Coloured 
i 
 
Helicobacter Pylori Eradication Therapy       Yes/No 
 
 
Post Transplant 
 
Induction Therapy 
Agent Dose 
  
  
  
 
Maintenance Therapy 
Agent Dose and Frequency 
  
  
  
 
MMF Dose Adjustment 
Date Amount Possible Reason 
   
   
   
   
i 
   
 
Rejection Episode 
Date Biopsy Result 
  
  
  
  
  
 
Steroid Pulse 
Dates 
 
Total Number 
Over how many years 
 
GI Complication 
Diagnosis Method Date 
   
   
   
   
 
 
 
i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexure 2 
 
Record Number Patient Name Date of Birth 
   
   
i 
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